Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma
Interventions: XyCAM with oxygen; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: No Intervention; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Wheaton, Illinois

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more

Conditions: Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%, Timolol 0.05% eye drops; Drug
Lead sponsor: Tavo Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Lynchburg, Virginia

Conditions: Glaucoma
Interventions: Latanoprost, Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Primary Open-angle Glaucoma
Interventions: Questionnaires; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Intraocular Pressure
Interventions: Increasing of intraocular pressure (IC); Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: RKI983A, Latanoprost; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 29
States / cities: Artesia, California • Inglewood, California • La Jolla, California + 25 more

Conditions: Glaucoma
Interventions: Restasis, Endura (artificial tears); Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Open Angle Glaucoma
Interventions: Glaucoma Surgery, InnFocus MicroShunt; Procedure · Device
Lead sponsor: InnFocus Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 24
States / cities: Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more

Conditions: Glaucoma, Suspect, Diabetic Retinopathy, Cataract, Refractive Errors, Vision Impairment and Blindness
Interventions: Intervention, Usual Care; Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Telephone and Print based intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate; Drug
Lead sponsor: Sylentis, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Artesia, California • Petaluma, California • Morrow, Georgia + 1 more

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve; Device
Lead sponsor: SOLX, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 9
States / cities: Petaluma, California • Littleton, Colorado • Tampa, Florida + 6 more

Conditions: Cataract, Macular Degeneration, Glaucoma
Interventions: Technology-based Eye Care Services (TECS) Protocol; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Glaucoma
Interventions: AI-based glaucoma screening, IOP measurement, Virtual Reality Visual Field Testing; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 7
States / cities: Boston, Massachusetts • Chelsea, Massachusetts • Lynn, Massachusetts + 2 more

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more

Conditions: Glaucoma, Cataract
Interventions: Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: The New York Eye Surgery Center; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Glaucoma
Interventions: Diopsys NOVA; Diagnostic Test
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma
Interventions: VISIOR video goggles; Device
Lead sponsor: Visior Technologies Ltd.; Industry
Eligibility: 30 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Ocular Blood Flow Imaging for Glaucoma Assessment

A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Impact of Glaucoma and Visual Field Loss on Life Space

IOP Elevation Study

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

InnFocus MicroShunt Versus Trabeculectomy Study

Eye Health Intervention Study in Upper Manhattan

Interactive Study to Increase Glaucoma Adherence to Treatment

SYL040012, Treatment for Open Angle Glaucoma

SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma

Technology-based Eye Care Services (TECS) Compare

The Glaucoma and Retinopathy Screening Study

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)

The Effects of Visior on Ocular Hemodynamics

Aqueous Outflow Facility Changes With Posture